Intracellular delivery is a key step in biological research and has enabled decades of
biomedical discoveries. It is also becoming increasingly important in industrial and medical …

The advent of immune checkpoint inhibition (ICI) using antibodies against PD1 and its
ligand PDL1 has prompted substantial efforts to develop complementary drugs. Although …

Recently, chimeric antigen receptor (CAR)-T cell therapy has shown great promise in
treating haematological malignancies,,,,,–. However, CAR-T cell therapy currently has …

Therapeutic applications of nuclease-based genome editing would benefit from improved
methods for transgene integration via homology-directed repair (HDR). To improve HDR …

Translation of the CRISPR–Cas9 system to human therapeutics holds high promise.
However, specificity remains a concern especially when modifying stem cell populations …

Chimeric antigen receptors (CARs) are synthetic receptors that redirect and reprogram T
cells to mediate tumour rejection. The most successful CARs used to date are those …

Decades of work have aimed to genetically reprogram T cells for therapeutic purposes,
using recombinant viral vectors, which do not target transgenes to specific genomic sites …

The success of chimeric antigen receptor (CAR) T cells targeting B-cell malignancies
propelled the field of synthetic immunology and raised hopes to treat solid tumors in a …

Intracellular delivery of materials has become a critical component of genome-editing
approaches, ex vivo cell-based therapies, and a diversity of fundamental research …

Although the signaling events that induce different forms of programmed cell death are well
defined, the subsequent immune responses to dying cells in the context of cancer remain …